A one-day gathering where patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers come together to co-create the future of genetic medicine
We are working to build a world with “genetic agency”: an individual’s ability to take action at the genetic level to live a healthier life. It’s a term we introduced to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To further the momentum, Dyno is hosting the 2nd Genetic Agency Technology Conference (GATC) in San Francisco on November 18.
The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all – and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone – it requires a community working together with pace to turn powerful emerging technologies into patient impact.
At GATC we’re bringing together leaders from various sectors: patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers. Topics at this meeting will include patient stories, AI for sequence design and therapeutic development, frontier genetic technologies, along with challenges and opportunities of interest to attendees in preclinical development, manufacturing and regulatory pathways.
Compared to other conferences, GATC puts greater emphasis on technological frontiers, firmly grounded in patient impact and including highly participatory sessions emphasizing conversation and connection. Our assumption is that everyone who attends comes with expertise and a goal.

Empower
Hear from patients directly as co-creators shaping the next generation of genetic technologies
Connect
Meet your next collaborator and build lasting relationships across the gene therapy ecosystem, united by a shared commitment to genetic agency
Imagine
Step into the future with sessions that reveal the technology trends shaping what’s next
Activate
Leave with optimism and the conviction to act to realize a world with genetic agency
Conference design: Misha Glouberman

Lowell M. Zeta
Acting Chief of Staff, Deputy Commissioner and Special Counsel, U.S. Food and Drug Administration

Aliza Apple, PhD
Vice President, Catalyze360 AI/ML, Eli Lilly

Carolyn Bertozzi, PhD
Nobel Laureate, Stanford Professor & Co-founder Grace Science LLC

Matt Wilsey
CEO, Grace Science LLC

Joy Jiao, PhD
Life Sciences Research Lead, OpenAI

Špela Miroševič, PhD
Founding President, CTNNB1 Foundation

Jacob Stern
CEO, Team Sid & GP, Even One Ventures

Richard Wilson, MBA
Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas

Namrata Anand
Founder & CEO, Diffuse Bio

George Apostol, MD
SVP, Clinical Development, uniQure

David Apple
Founder and CEO, Shark Tooth Bio

Robert Bell, PhD
Chief Scientific Officer, Ascidian Therapeutics

Yukari Blumenthal, MD
Discovery Research Medical Lead, Astellas

Andreas Borg
Founder at CURE5 Foundation

Tom Brennan
SVP of Nonclinical Operations, Mahzi Therapeutics

Luke Gilbert, PhD
Core Investigator, Arc Institute; Associate Professor, UCSF

Hani Goodarzi, PhD
Core Investigator and AI Research Lead, Arc Institute; Associate Professor, UCSF

Victoria Gray
Patient advocate, first patient treated with CRISPR gene editing therapy for Sickle Cell Disease

Andrew Grimm, MD, PhD
Vice President, Global Clinical Development for Metabolic Diseases, Ultragenyx

Jake Heller
Co-founder, Brain Repair Foundation

Miki Heller
Co-founder, Brain Repair Foundation

Brandon Henry, MD
Founder, Chief Executive & Medical Officer, Aurelix Bio

Elliot Hershberg, PhD
Partner at Amplify and Author of The Century of Biology

Ian Huyett, JD
Board Member, Granite Bio Innovation

Jainu Jogani
Co-founder, Child's Cure Genetic Research

Jo Kaur
Founder, Riaan Research Initiative

Gleb Kuznetsov, PhD
Co-Founder & CEO, Manifold Bio

Michelle Lee
Founder and CEO, Medra

Alex LeNail, PhD
Postdoctoral Researcher at the Wyss Institute, Harvard Medical School

Boaz Levi, PhD
Co-founder & CEO, Epicure

Leszek Lisowski, PhD, MBA
Unit Head, Children's Medical Research Institute; Professor, University of Sydney

Alan Mardinly, PhD
Chief Scientific Officer, Science Corporation

Rachel McMinn, PhD
Founder & CEO, Neurogene

Kate Nudel
Director, Program and Alliance Management, Manifold Bio

Gabriel Ocana Santero, PhD
CEO and Co-founder, Exin Therapeutics

Nicole (Niki) Paulk, PhD
Founder, CEO and President, Siren Biotechnology

William (Bill) Peranteau, MD
Fetal and Pediatric Surgeon, Children's Hospital of Philadelphia

Stanley Qi, PhD
Professor, Stanford University; Co-founder, Epicrispr Biotechnologies

Stevie Ringel
Founder & CEO at Nome, President at Kizuna Foundation

Sam Rodriques
CEO, Co-Founder at Edison

Giuseppe Ronzitti, PhD
Director of Research Strategy, Genethon; Research Director, Inserm

Sean Russell
Managing Partner, PrimeRA Pharma Partners

Pablo Sardi, PhD
Senior Vice President, Rare and Neurologic Diseases Research, Sanofi

Yiwei She, PhD
Founder & CEO, TNPO2 Foundation

Kevin A. Strauss, MD
Founder and CEO, Plowshare Therapies

Dean Suhr
President & Cofounder at MLD Foundation

Joseph Sullivan, MD
VP Clinical Development, Encoded Therapeutics

Ruxandra Teslo, PhD
Writer, Stripe Press

Lijun Wang
Founder and CEO, CoJourney

Stefan Weigand, PhD
Chief Scientific Officer, BigHat Biosciences

Sajith Wickramasekara
Co-founder & CEO, Benchling
November 18, 2026
8:00am
8:30am
11:00am to 12:00pm
12:00pm to 1:00pm
1:00pm to 2:00pm
2:00pm
2:20pm
5:35pm
Last November, the inaugural GATC brought together 200 leaders in Boston, from patient advocates and therapeutic developers to technologists and regulators. Speakers included Victoria Gray, George Church, Sonia Vallabh, Terence Flotte, Sylke Poehling, and Allyson Berent. The result was a day of stimulating conversation, new connections, and energy to build a movement.
0+
attendees
0
unique speakers
0
talks
0+
minutes of open social time





